Estimates of the impact of a new drug on US health care budgets: are published studies done well?
An analysis to estimate the impact of a new drug on health care budgets (budget impact analysis) is desired by many US health plans before adding a new drug to their formulary and providing insurance coverage. However, previous reviews of budget impact analyses have indicated that published analyses often do not use methods that are recommended in guidelines published by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
In our review, we assess the extent to which published US budget impact analyses for new drugs use the recommended methods. We describe recommended methods for seven key elements (Tab. 1). US studies reporting estimates of the budget impact of a new drug were identified by searching the MEDLINE database. The primary finding from this review is that recommended methods are not followed in many published budget impact analyses. For example, we found that growth in the treated population size and/or changes in disease-related costs expected over the next 3 to 5 years for more effective treatments were not included in several budget impact analyses for health conditions that last for many years. In addition, all drug-related costs were not captured in the majority of the analyses. Finally, for most studies, analyses testing the impact on the results of varying the base case selected for the seven key elements were very limited, and the ranges used for alternative input parameter values were frequently selected without justification or data to support them.
The conclusions from our review are that ISPOR guidelines are frequently not followed in US analyses which may result in over- or underestimates of the budget impact of new drugs. In addition, if published budget impact analyses are to be useful for US budget holders it is also important for published budget-impact analyses to present the results of many different analyses based on realistic alternative scenarios for the inputs that vary by budget holder.
Josephine Mauskopf, Stephanie Earnshaw
RTI Health Solutions, RTP, NC, USA
A Methodological Review of US Budget-Impact Models for New Drugs.
Mauskopf J, Earnshaw S
Pharmacoeconomics. 2016 Nov